Slingshot members are tracking this event:

Following approval recommendation from FDA Advisory Committee for CTL-019 in pediatric Acute lymphoblastic leukemia (ALL), Novartis to submit drug to Europe for approval by end of 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
NVS Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Recommendation For Approval, Ctl-019, Acute Lymphoblastic Leukemia, Ema Submission